Valuation: Vectura Group

Market Cap 1B 895M 821M 746M 1.4B 94.94B 1.43B 9.81B 3.93B 50.25B 3.77B 3.69B 159B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 829M 760M 691M 1.3B 87.91B 1.33B 9.09B 3.64B 46.53B 3.49B 3.42B 147B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
30/10/25 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
16/09/24 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
16/04/24 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
28/12/21 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
03/12/21 Philip Morris CEO does not need M&A to hit smoke free goals RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/12/21 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
10 years 59.1
Extreme 59.1
180.88
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 31/05/2016
Corporate Secretary - 29/06/2025
Director TitleAgeSince
Director/Board Member 53 14/09/2023
Director/Board Member 57 29/06/2025
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/21 Exercice 81,089 0.0133%
01/10/21 Sell 119,429 0.0196%
01/10/21 Exercice 1,928,114 0.3160%

Financials

2019 2020
Net sales 178M 159M 146M 132M 249M 16.85B 255M 1.74B 698M 8.92B 669M 655M 28.25B 191M 170M 156M 142M 266M 18.01B 272M 1.86B 746M 9.53B 715M 700M 30.2B
Net income -22.1M -19.69M -18.06M -16.41M -30.85M -2.09B -31.56M -216M -86.53M -1.11B -82.95M -81.18M -3.5B 122M 109M 100M 90.9M 171M 11.57B 175M 1.2B 479M 6.12B 459M 450M 19.39B
Net Debt -66.5M -59.26M -54.34M -49.39M -92.84M -6.28B -94.96M -650M -260M -3.33B -250M -244M -10.54B -74.4M -66.3M -60.8M -55.25M -104M -7.03B -106M -727M -291M -3.72B -279M -273M -11.79B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-